Vitamin D
Other / unclassified targets CRH, VDR via inhibition
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | US (FDA) | VITAMIN D | — | 1973-03-26 | fda.gov ↗ |
Trials 153 · started per year
Also used as a comparator or background therapy in 105 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT03629717 Background | Jun → Dec 2018 | female breast carcinoma | Washington University School of Medicine | Completed | No outcome recorded |
| Phase 15 trials | ||||||
| Phase 1 | NCT02043171 Comparator | Aug 2014 → Feb 2019 | muscular atrophy | Metabolic Technologies Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01395589 Comparator | Feb 2011 → Jan 2014 | asthma, vitamin D deficiency | Hamad Medical Corporation | Completed | No outcome recorded |
| Phase 1 | NCT01855321 Comparator | Aug 2010 → Mar 2015 | type 2 diabetes mellitus | University of Florida | Completed | No outcome recorded |
| Phase 1 | NCT00585637 Comparator | Oct 2007 → Oct 2010 | digestive system cancer, hypertensive disorder, prostate cancer | Dana-Farber Cancer Institute | Completed | No outcome recorded |
| Phase 1 | NCT00006196 Background | — | osteoporosis | National Center for Research Resources (NCRR) | Completed | No outcome recorded |
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT06458686 Comparator | Jun 2024 → Jun 2026 overdue | psychiatric disorder | German University in Cairo | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT05552729 Comparator | Sep → Dec 2022 | cognitive impairment with or without cerebellar ataxia, digestive system neoplasm | Yangzhou University | Unknown | No outcome recorded |
| Phase 1/2 | NCT04660786 Comparator | Nov 2021 → Dec 2022 | alopecia areata | Alexandria University | Unknown | No outcome recorded |
| Phase 217 trials | ||||||
| Phase 2 | NCT07293910 Comparator | Feb → Dec 2026 expected | Helicobacter pylori infectious disease | Tanta University | Recruiting | No outcome recorded |
| Phase 2 | NCT05852496 Comparator | Jul 2023 → Jul 2024 | peripheral neuropathy, vitamin D deficiency | Assiut University | Unknown | No outcome recorded |
| Phase 2 | NCT04262479 Background | Mar 2020 → May 2022 | latent autoimmune diabetes in adults | Norwegian University of Science and Technology | Completed | No outcome recorded |
| Phase 2 | NCT03186131 Comparator | Oct 2017 → Dec 2022 | osteoporosis | Shinshu University | Unknown | No outcome recorded |
| Phase 2 | NCT03192059 Background | Jul 2017 → Jun 2021 | cervical cancer, endometrial cancer | University Hospital, Ghent | Completed | No outcome recorded |
| Phase 2 | NCT02944799 Comparator | Dec 2015 → Dec 2021 | osteoporosis, rheumatoid arthritis | University of Aarhus | Completed | No outcome recorded |
| Phase 2 | NCT01988090 Comparator | Dec 2013 → Jul 2018 | breast cancer | Mothaffar Rimawi | Terminated | No outcome recorded |
| Phase 2 | NCT01785108 Comparator | Feb 2013 → Mar 2017 | type 1 diabetes mellitus | Johnny Ludvigsson | Completed | No outcome recorded |
| Phase 2 | NCT01739855 Comparator | Nov 2012 → Jul 2014 | — | Medical University of Vienna | Completed | No outcome recorded |
| Phase 2 | NCT01754961 Comparator | Nov 2011 → Oct 2013 | hepatitis C virus infection, vitamin D deficiency | Veterans Medical Research Foundation | Unknown | No outcome recorded |
| Phase 2 | NCT01465893 Comparator | Jul 2011 → Jul 2012 | optic neuritis | Isfahan University of Medical Sciences | Unknown | No outcome recorded |
| Phase 2 | NCT01210521 Comparator | Sep 2010 → Feb 2016 | asthma | Florida Atlantic University | Withdrawn | No outcome recorded |
| Phase 2 | NCT01093417 Comparator | Jan → Oct 2010 | HIV infectious disease, vitamin D deficiency | University Hospitals Cleveland Medical Center | Completed | No outcome recorded |
| Phase 2 | NCT01331148 Comparator | Feb 2009 → Dec 2011 | sickle cell disease | Wake Forest University Health Sciences | Completed | No outcome recorded |
| Phase 2 | NCT00752557 Comparator | Dec 2008 → Apr 2015 | osteoporosis | Pfizer | Completed | No outcome recorded |
| Phase 2 | NCT00172068 Background | Jan 2002 → Nov 2008 | breast cancer | Novartis Pharmaceuticals | Terminated | No outcome recorded |
| Phase 2 | NCT00061256 Background | ? → Sep 2006 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 2/33 trials | ||||||
| Phase 2/3 | NCT05495958 Comparator | Jul → Oct 2022 | eye adnexa disorder | Shahid Beheshti University of Medical Sciences | Unknown | No outcome recorded |
| Phase 2/3 | NCT05008484 Background | Oct 2021 → Jun 2024 | spinal cord injury | VA Office of Research and Development | Completed | No outcome recorded |
| Phase 2/3 | NCT01523496 Comparator | Dec 2011 → Aug 2016 | HIV infectious disease | University Hospitals Cleveland Medical Center | Completed | No outcome recorded |
| Phase 320 trials | ||||||
| Phase 3 | NCT06964334 Comparator | Jun 2025 → Jun 2026 overdue | Helicobacter pylori infectious disease | Assiut University | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06729840 Comparator | Dec 2024 → Apr 2025 overdue | keloid formation | Sohag University | Recruiting | No outcome recorded |
| Phase 3 | NCT03930992 Comparator | Apr 2019 → Oct 2022 | osteoporosis | University of Guadalajara | Completed | No outcome recorded |
| Phase 3 | NCT04468711 Comparator | Jun → Dec 2018 | atopic eczema | National Hepatology & Tropical Medicine Research Institute | Completed | No outcome recorded |
| Phase 3 | NCT03396380 Comparator | Jul 2017 → Mar 2018 | female infertility | Ain Shams University | Unknown | No outcome recorded |
| Phase 3 | NCT02915705 Comparator | Sep 2016 → Feb 2018 | X-linked hypophosphatemic rickets | Kyowa Kirin, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT02022475 Comparator | Dec 2013 → May 2015 | vitamin D deficiency | University of Zurich | Completed | No outcome recorded |
| Phase 3 | NCT02030041 Comparator | Dec 2013 → Dec 2015 | hyperlipidemia | Post Graduate Institute of Medical Education and Research, Chandigarh | Completed | No outcome recorded |
| Phase 3 | NCT01768039 Comparator | Mar 2013 → Aug 2014 | multiple sclerosis | Mazandaran University of Medical Sciences | Unknown | No outcome recorded |
| Phase 3 | NCT01748448 Comparator | Dec 2012 → Jul 2022 | cutaneous melanoma | Universitaire Ziekenhuizen KU Leuven | Completed | No outcome recorded |
| Phase 3 | NCT01522521 Background | Feb 2012 → Jan 2015 | osteoporosis | Asahi Kasei Therapeutics Corporation | Completed | No outcome recorded |
| Phase 3 | NCT01183442 Comparator | Jun 2010 → Nov 2012 | coronary artery disorder, hyperglycemia, vitamin D deficiency | Medical University of Graz | Terminated | No outcome recorded |
| Phase 3 | NCT00824993 Background | Dec 2008 → Apr 2017 | hematopoietic and lymphoid cell neoplasm | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 3 | NCT00757393 Background | Sep 2008 → Sep 2015 | osteoporosis | The Hospital for Sick Children | Completed | No outcome recorded |
| Phase 3 | NCT00548379 Comparator | Nov 2007 → Jun 2009 | pneumonia, vitamin D deficiency | London School of Hygiene and Tropical Medicine | Unknown | No outcome recorded |
| Phase 3 | NCT00404820 Background | Oct 2006 → Dec 2008 | osteoporosis | Novartis | Completed | No outcome recorded |
| Phase 3 | NCT00352846 Background | Jan 2006 → Sep 2011 | non-Hodgkin lymphoma | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 3 | NCT00500409 Comparator | Dec 2005 → Dec 2006 | osteoporosis | Virchow Group | Completed | No outcome recorded |
| Phase 3 | NCT00043719 Background | Jul 2002 → Dec 2007 | osteoporosis | National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) | Completed | No outcome recorded |
| Phase 3 | NCT00103740 Background | Apr 2002 → Dec 2003 | bone Paget disease | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 431 trials | ||||||
| Phase 4 | NCT07245277 Comparator | Aug → Dec 2025 | neonatal sepsis | Padjadjaran University | Completed | No outcome recorded |
| Phase 4 | NCT05630768 Background | Jan 2023 → Jul 2025 | postmenopausal osteoporosis | Dong-A ST Co., Ltd. | Completed | No outcome recorded |
| Phase 4 | NCT06716476 Comparator | Mar 2022 → Mar 2023 | rheumatoid arthritis | University of Pristina | Completed | No outcome recorded |
| Phase 4 | NCT05244018 Comparator | Mar → Oct 2022 | infectious disease with sepsis | Ain Shams University | Completed | No outcome recorded |
| Phase 4 | NCT05203588 Background | Oct 2021 → Oct 2022 | osteoporosis | Shanghai Changzheng Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT05037253 Comparator | Oct 2020 → May 2021 | COVID-19 | Federal State Budgetary Institution, V. A. Almazov Federal North-West Medical Research Centre, of the Ministry of Health | Completed | No outcome recorded |
| Phase 4 | NCT03904680 Comparator | Apr → Oct 2019 | psoriasis | Cairo University | Unknown | No outcome recorded |
| Phase 4 | NCT03806036 Comparator | Jan 2018 → Feb 2019 | polycystic ovary syndrome | Cairo University | Unknown | No outcome recorded |
| Phase 4 | NCT03385356 Comparator | Dec 2017 → Apr 2018 | relapsing-remitting multiple sclerosis, vitamin D deficiency | University Medical Centre Maribor | Completed | No outcome recorded |
| Phase 4 | NCT02664857 Comparator | Jul 2016 → Dec 2020 | — | Cukurova University | Completed | No outcome recorded |
| Phase 4 | NCT02367599 Comparator | Dec 2014 → Jun 2018 | — | University of California, San Diego | Completed | No outcome recorded |
| Phase 4 | NCT02112734 Comparator | Dec 2014 → Apr 2028 expected | food allergy | Murdoch Childrens Research Institute | Active not recruiting | No outcome recorded |
| Phase 4 | NCT02053402 Comparator | Mar 2014 → Jan 2015 | chronic asthma | University of Limpopo | Unknown | No outcome recorded |
| Phase 4 | NCT02054182 Comparator | Feb → Nov 2014 | bronchiolitis, pneumonia | University of Limpopo | Unknown | No outcome recorded |
| Phase 4 | NCT02090400 Background | May 2013 → Jul 2015 | postmenopausal osteoporosis | Instituto Palacios | Completed | No outcome recorded |
| Phase 4 | NCT02010762 Comparator | Feb 2013 → Dec 2017 | Crohn disease | Academic Medical Center - University of Amsterdam | Completed | No outcome recorded |
| Phase 4 | NCT01753856 Background | Jan 2013 → Jun 2014 | osteoporosis | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 4 | NCT01709110 Background | Oct 2012 → Jul 2016 | postmenopausal osteoporosis | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 4 | NCT01400516 Background | Aug 2011 → Jul 2015 | rheumatoid arthritis | Brigham and Women's Hospital | Completed | No outcome recorded |
| Phase 4 | NCT01386736 Comparator | Apr 2011 → Mar 2012 | obesity disorder, vitamin D deficiency | Weill Medical College of Cornell University | Unknown | No outcome recorded |
| Phase 4 | NCT01222026 Comparator | Sep 2010 → Dec 2014 | osteoporosis, primary hyperparathyroidism | Medical University of Vienna | Completed | No outcome recorded |
| Phase 4 | NCT00803712 Comparator | Feb 2009 → Dec 2010 | chronic kidney disease, secondary hyperparathyroidism of renal origin | Amgen | Completed | No outcome recorded |
| Phase 4 | NCT00765687 Comparator | Aug 2008 → May 2012 | metastatic carcinoma in the bone, non-small cell lung carcinoma | Sun Yat-sen University | Completed | No outcome recorded |
| Phase 4 | NCT00666367 Comparator | Jan 2008 → Jun 2010 | chronic obstructive pulmonary disease | KU Leuven | Completed | No outcome recorded |
| Phase 4 | NCT01578434 Comparator | Nov 2007 → Feb 2009 | rickets | Lady Hardinge Medical College | Completed | No outcome recorded |
| Phase 4 | NCT00869622 Comparator | Jun 2006 → Oct 2012 | disease of bone structure, epilepsy, osteoporosis | Boston VA Research Institute, Inc. | Completed | No outcome recorded |
| Phase 4 | NCT00271713 Comparator | Mar 2006 → Sep 2007 | postmenopausal osteoporosis | Charite University, Berlin, Germany | Completed | No outcome recorded |
| Phase 4 | NCT00303485 Background | Feb 2006 → Jun 2007 | postmenopausal osteoporosis | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 4 | NCT00160264 Background | Jan 2003 → ? | osteoporosis | Solvay Pharmaceuticals | Completed | No outcome recorded |
| Phase 4 | NCT00616694 Background | Jul 2002 → Dec 2004 | osteoporosis | Sanofi | Completed | No outcome recorded |
| Phase 4 | NCT01882400 Background | May 2001 → Sep 2007 | cystic fibrosis, muscular dystrophy, osteoporosis | Gilles Boire | Completed | No outcome recorded |
| Phase not applicable25 trials | ||||||
| — | NCT07543926 Comparator | Apr → Nov 2026 expected | common wart | Sohag University | Not yet recruiting | No outcome recorded |
| — | NCT07458815 Comparator | Mar 2026 → Aug 2027 expected | intracerebral hemorrhage | The University of Hong Kong | Recruiting | No outcome recorded |
| — | NCT07334626 Background | Jan → Jul 2026 overdue | breast cancer, osteoporosis | Benha University | Recruiting | No outcome recorded |
| — | NCT07096037 Comparator | Sep 2025 overdue | Osgood-Schlatter disease | Faculty of Medicine, Sousse | Not yet recruiting | No outcome recorded |
| — | NCT05091203 Comparator | Nov 2022 → Oct 2023 | — | Assiut University | Completed | No outcome recorded |
| — | NCT05452512 Background | Jul → Dec 2022 | — | Seoul National University Hospital | Completed | No outcome recorded |
| — | NCT05717569 Comparator | May → Nov 2022 | cirrhosis of liver | Ain Shams University | Completed | No outcome recorded |
| — | NCT05901337 Background | Mar → Jun 2022 | — | Cairo University | Completed | No outcome recorded |
| — | NCT05977166 Comparator | Mar → Jun 2022 | long COVID-19 | Cairo University | Completed | No outcome recorded |
| — | NCT04555317 Background | May 2021 → Aug 2025 | female reproductive organ cancer | The Christie NHS Foundation Trust | Unknown | No outcome recorded |
| — | NCT04759729 Background | Dec 2020 → Feb 2021 | — | Medical University of Gdansk | Unknown | No outcome recorded |
| — | NCT03884036 Comparator | Jul → Aug 2019 | — | Hangang Sacred Heart Hospital | Unknown | No outcome recorded |
| — | NCT02735187 Comparator | Mar → Aug 2016 | psoriasis | Philips Electronics Nederland BV | Completed | No outcome recorded |
| — | NCT02297568 Comparator | Mar 2014 → Jun 2015 | vitamin D deficiency | Department of Medical Services Ministry of Public Health of Thailand | Completed | No outcome recorded |
| — | NCT01185808 Comparator | Oct 2013 | chronic rhinosinusitis | Medical University of South Carolina | Withdrawn | No outcome recorded |
| — | NCT01419821 Comparator | Sep 2013 → Sep 2014 | vitamin D deficiency | Meir Medical Center | Unknown | No outcome recorded |
| — | NCT02215213 Comparator | Jun 2013 → Jul 2015 | pregnancy disorder | Aga Khan University | Completed | No outcome recorded |
| — | NCT01724190 Comparator | Nov 2012 → Jun 2014 | type 1 diabetes mellitus | Nationwide Children's Hospital | Completed | No outcome recorded |
| — | NCT04443387 Comparator | Apr 2012 → Apr 2014 | — | Dubai Health Authority | Completed | No outcome recorded |
| — | NCT02058186 Comparator | Dec 2011 → Dec 2012 | atopic eczema | Srinakharinwirot University | Completed | No outcome recorded |
| — | NCT01151397 Comparator | Aug 2011 → Feb 2012 | chronic hepatitis C virus infection | Ziv Hospital | Unknown | No outcome recorded |
| — | NCT01146626 Comparator | Aug 2011 → Feb 2012 | chronic hepatitis C virus infection | Ziv Hospital | Unknown | No outcome recorded |
| — | NCT01023490 Comparator | Jan 2010 → Oct 2012 | vitamin D deficiency | Tel-Aviv Sourasky Medical Center | Completed | No outcome recorded |
| — | NCT00204919 Comparator | Jun 2001 → May 2004 | osteoporosis, vitamin D deficiency | University of Wisconsin, Madison | Completed | No outcome recorded |
| — | NCT00536653 Comparator | Oct 1999 → Jan 2007 | osteoporosis | Wirral University Teaching Hospital NHS Trust | Completed | No outcome recorded |
Press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-05-12 | AstraZeneca | Eneboparatide normalised serum calcium and achieved independence from active vitamin D and oral calcium supplements in 31.1% of adults with hypoparathyroidism at week 24 in CALYPSO Phase III trial astrazeneca.com ↗ |
| 2013-05-31 | Daiichi Sankyo | Daiichi Sankyo Launches Denotas® Chewable Combination Tablets with Calcium/Natural Vitamin D3/Magnesium daiichisankyo.com ↗ |
Evidence & citations 24 cited values
Every value below carries the sentence it was read from. 268 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | vitamin D | “Fat-soluble vitamins is administered 0.5 piece/kg (equals to 1150 U/kg vitamin A，200 U/kg vitamin D, 3.2 U/kg vitamin E) intravenously every day until the baby achieve full...” NCT03876704 ↗254“supplemented with oral Vitamin D 400 IU/day (Devit-3 Oral Drop, 50000 IU/15 ml, Deva Company, Turkey) started when achieved 75%of total nutrition by enteral feedings and...” NCT02941185 ↗ “G2 group receives 1200 mg of calcium and 400 IU of vitamin D supplements per day, 35 mg of risedronate per week, but do not participate in strength/weight training exercises.” NCT00567606 ↗ “Participants will be given dietary supplement powder containing protein, galactooligosaccharide (GOS), vitamin D, and calcium throughout the twelve weeks of intervention.” NCT05354310 ↗ “Immunomodulatory Effect of Vitamin D after Allogeneic Stem Cell Transplantation: Results of a Prospective Multicenter Clinical Trial.” PMID 27358490 ↗ Jun 2016 “oral administration of 303mg of silybin-phospholipid complex, 10mg of vitamin D, and 15mg of vitamin E, twice a day for six months” NCT04640324 ↗ “Single capsule with 80mg low-dose aspirin, 1.2 grams calcium, 600 IU vitamin D, 5mg folic acid and 1000 ug vitamin B12 mixed.” NCT02007837 ↗ “calcium plus vitamin D (calcium+D) supplementation (600 mg elemental calcium and 5 microg vitamin D, consumed twice a day)” PMID 19263591 ↗ Mar 2009 “Administer Osteoform 20 µg daily subcutaneously and 1000 mg calcium and 500 IU vitamin D orally for 180 days” NCT00500409 ↗ “2 Arm (HIV+): will receive Zoledronic acid 4mg and standard treatment (vitamin D and calcium carbonate)” NCT03930992 ↗ “Vitamin D: The recommended dietary dose of vitamin D is 600 IU each day for adults 70 and younger” NCT05901337 ↗ “receiving vitamin D capsules or a placebo (1 capsule daily, each containing 600 IU of vitamin D)” PMID 37969936 ↗ Oct 2023 “Actonel 5 mg orally once daily (OD), calcium 500 mg + vitamin D 200 units twice daily (BID)” NCT00616694 ↗ “Preoperative vitamin D prevents postoperative transient hypocalcemia after thyroidectomy .” NCT04094493 ↗ “traditional medical treatment in form of (vitamin D, vitamin C and anticoagulation drugs” NCT05977166 ↗ “(b) calcium and vitamin D (c) calcium, vitamin D and bisphosphonate (alendronate)” NCT04555317 ↗ “Vitamin D is a fat soluble vitamin used for the treatment of many diseases.” NCT06458686 ↗ “Co-administration with Zometa: Calcium 500 mg + vitamin D 400-500 IU daily” NCT00765687 ↗ “Oral Azithromycin , Cetirizine, Paracetamol, Zinc, Vitamin C, Vitamin D” NCT04935515 ↗ “zoledronic acid (i.v.)/year + daily calcium and vitamin D for 2 years” NCT01522521 ↗ “Vitamin D , botox , tramcinolone intralesionally injected in keloid” NCT06729840 ↗ “Vitamin D Supplementation and CD4 Count in HIV-Infected Children” NCT00911664 ↗ “2g Strontium Ranelate once daily 1000mg Calcium 800 IE Vitamin D” NCT01222026 ↗ “Vitamin D (D-cure) will be administered by monthly oral intake.” NCT00666367 ↗ “Treatment with Calcium, vitamin D and a weekly bisphosphonate.” NCT01882400 ↗ “Vitamin D 400 units by mouth 2 times a day for 12 months” NCT00824993 ↗ “Vitamin D 300 mcg by mouth once daily for 12 weeks” NCT00907153 ↗ “daily vitamin D supplementation” NCT06913413 ↗ “Dietary Supplement: Vitamin D” NCT07400757 ↗ “1000 IU Vitamin D” NCT03981562 ↗ “Drug: Vitamin D” NCT01176344 ↗ “Drug: Vitamin D” NCT01908751 ↗ |
| Known as | active vitamin D | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07381998 ↗ |
| Known as | Calciferol | “Vitamin D (Calciferol) in oral solution. Dosage and interval: 2000 IU daily for 120 days” NCT02352974 ↗ |
| Known as | cholecalciferol | “Participants will be randomly assigned in a 1:1 ratio to receive either monthly high-dose vitamin D supplementation (50,000 IU cholecalciferol) for 6 months or standard...” PMID 42392859 ↗ Jun 20266“INTERVENTION: Participants were randomly assigned to receive oral cholecalciferol (vitamin D3) supplements of 400 IU/d (n=39), 800 IU/d (n=39), 1200 IU/d (n=38), or 1600 IU/d (n=16).” PMID 23632722 ↗ May 2013 “Women were randomized at their first or second annual visit to receive a dose of 1000 mg of elemental calcium plus 400 IU of cholecalciferol (vitamin D) or placebo daily.” PMID 17502530 ↗ May 2007 “Cholecalciferol (Vitamin D) is a fat-soluble vitamin that is involved in maintaining the serum calcium-phosphorus gradient.” NCT05037253 ↗ “vitamin D (an aqueous preparation of cholecalciferol (Devarol® ampoule 200,000 IU/2 mL, Memphis, Egypt)” NCT04660786 ↗ “Vitamin D3 - cholecalciferol, oral suspension in drops, will be prescribed as follows:” NCT03356730 ↗ “Each film coated tablet of vitamin D contains 50,000 IU Vitamin D3 (Cholecalciferol).” NCT05331807 ↗ |
| Known as | Cholecalciferol (D2) | “The intervention group will receive VD Cholecalciferol (D2) 50,000 I.U once weekly for 12 weeks, followed by 50,000 I.U once every fortnight for 24 weeks” NCT03989778 ↗ |
| Known as | D- Dep | “vitamin D (D- Dep) from day 20 of the preceding cycle till the day of HCG administration” NCT05091203 ↗ |
| Known as | D-cure | “Vitamin D (D-cure) will be administered by monthly oral intake.” NCT00666367 ↗ |
| Known as | Daivonex | “Treatment of contralateral localized psoriasis vulgaris plaque with Vitamin D creme (Daivonex)” NCT02735187 ↗ |
| Known as | Decristol | “Decristol (cholecalciferol) 20000 IU per capsule” NCT01846026 ↗ |
| Known as | Devarol | “vitamin D (an aqueous preparation of cholecalciferol (Devarol® ampoule 200,000 IU/2 mL, Memphis, Egypt)” NCT04660786 ↗ |
| Known as | Devit-3 Oral Drop | “supplemented with oral Vitamin D 400 IU/day (Devit-3 Oral Drop, 50000 IU/15 ml, Deva Company, Turkey) started when achieved 75%of total nutrition by enteral feedings and...” NCT02941185 ↗ |
| Known as | Hydroferol | “The active treatment will be vitamin D (Hydroferol soft capsules of 0.266 mg).” NCT04621058 ↗ |
| Known as | ossofortin | “oral Vitamin D (ossofortin®, EVA PHARMA) 10,000 IU twice weekly and calcium (calciprex®, Marcyrl Pharmaceutical Industries) 1250 mg twice daily” PMID 32363556 ↗ May 20201“Vitamin D (ossofortin®, Eva Pharma)” NCT04916925 ↗ |
| Known as | sunshine vitamin | “Vitamin D, also known as the sunshine vitamin, has long been known to be a hormone that regulates calcium-phosphorous homeostasis and safeguards the integrity of the skeletal system .” NCT03874975 ↗ |
| Known as | Vigantol Oil | “Vitamin D - Vigantol® Oil” NCT03103152 ↗ |
| Known as | VIT D "SOLGAR" | “VIT D "SOLGAR"” NCT01417923 ↗ |
| Known as | vitamin d (Oleovit) | “vitamin d (Oleovit®)” NCT01183442 ↗ |
| Known as | Vitamin D3 | “It aimed to assess the effects of omega-3 fatty acids (ω3) and vitamin D3 (VitD) supplementation on the nutritional status of newly diagnosed women with breast cancer (BC) in...” PMID 39599746 ↗ Nov 20248“We conducted a randomized, double-blind, placebo-controlled trial of supplemental oral vitamin D (placebo, 1,000, 2,000, or 4,000 IU/day of vitamin D3 orally for 3 months) in...” PMID 24327720 ↗ Dec 2013 “OBJECTIVES: We aimed to investigate the pharmacokinetics of oral 25-hydroxyvitamin D3 [25(OH)D3] and oral vitamin D3 in healthy participants with differing BMI and...” PMID 34008842 ↗ Sep 2021 “INTERVENTION: Participants were randomly assigned to receive oral cholecalciferol (vitamin D3) supplements of 400 IU/d (n=39), 800 IU/d (n=39), 1200 IU/d (n=38), or 1600 IU/d (n=16).” PMID 23632722 ↗ May 2013 “Participants were randomly assigned to receive monthly treatment with oral vitamin D3 (50,000 IU; n = 209) or an identical placebo (n = 204) for 2 years.” PMID 26954409 ↗ Mar 2016 “Participants were randomized to a single oral dose of 500 000 IU of vitamin D3 or matching placebo.” PMID 35622854 ↗ May 2022 “Vitamin D3 - cholecalciferol, oral suspension in drops, will be prescribed as follows:” NCT03356730 ↗ “Oral vitamin D3 tablet, 60,000 IU weekly for 2 months (8 doses)” NCT03133299 ↗ “weekly: 16.000 IU oral vitamin D3 (calciferol)” NCT01739855 ↗ |
| Known as | Vitamin D: Cholecalciferol | “Vitamin D (Cholecalciferol)” NCT02043171 ↗1“Vitamin D: Cholecalciferol” NCT00874575 ↗ |
| Known as | VitD | “Long prescribed to maintain calcium balance and bone health, Vitamin D (VitD) supplement has also shown beneficial effects in preclinical models of brain diseases, including...” NCT07458815 ↗7“It aimed to assess the effects of omega-3 fatty acids (ω3) and vitamin D3 (VitD) supplementation on the nutritional status of newly diagnosed women with breast cancer (BC) in...” PMID 39599746 ↗ Nov 2024 “Vitamin D (VitD) deficiency is a significant public health concern in many areas around the globe” NCT04443387 ↗ “300.000 I.U single dose of VIT D IM injection” NCT03806036 ↗ “Drug: Vit D” NCT03981562 ↗ |
| Action | Activate | “vitamin D regulates renin transcription by activating the vitamin D receptor (VDR).” NCT01092130 ↗ |
| Modality | Other / unclassified | “Vitamin D supplementation” NCT01185808 ↗ |
| Route | Oral | “once-monthly vitamin D oral capsules (50,000 units)” NCT00204919 ↗ |
| Target | VDR | “vitamin D regulates renin transcription by activating the vitamin D receptor (VDR).” NCT01092130 ↗ |